Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
No adverse reproductive toxicity effects
Link to relevant study records
- Endpoint:
- extended one-generation reproductive toxicity - basic test design (Cohorts 1A, and 1B without extension)
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: guideline study with modifications, under GLP
- Justification for type of information:
- An analogue approach is used for the hazard assessment of several human health endpoints. The hypothesis for the analogue approach is that data can be read-across from data-rich substances, namely acetyl tributyl citrate (ATBC, CAS 77-90-7), acetyl triethyl citrate (CAS 77-89-4) and triethyl citrate (TEC, CAS 77-93-0) to acetyl trihexyl citrate (ATHC, CAS 24817-92-3). The analogue approach is based on common breakdown products via physical and biological processes, and similar functional groups, according to Annex XI, Section 1.5, of Regulation EC No. 1907/2006. Read-across to ATHC is indicated in order to avoid unnecessary in vivo testing according to Article 25 of Regulation EC No. 1907/2006.
The analogue approach to evaluating the safety of triethyl citrate is adopted here, reflecting the approach used by various expert panels and authoritative bodies in their safety assessment of TEC, included JECFA, EFSA, U.S. FDA, EPA and CIR. The use of analogues for hazard evaluation is justified (Scenarios 1 and 2 of the RAAF, 2015) because the substances have common breakdown products via physical and biological processes, which reflects the similar functional groups in their chemical structure. The proposed analogues have similar functional groups, including: a citric acid (tricarboxylic acid) backbone, three short-chain alkyl esters, and an acetyl group (except for TEC). Other than the acetyl group, there are no other functional groups which may introduce additional toxicities. The substances display similar classification based on similar toxicities.
The target substance is expected to have essentially the same effect in the toxicity test/endpoint as does the source substance. Dose descriptors obtained for derivation of a DNEL are adequate and appropriate, and do not underestimate the hazards of the registered substance.
This information is adequate to fulfill the data requirements of Annex IX, to be the basis for classification and labelling decisions, and for risk assessment. - Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- other: OECD 408 with in utero phase
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 443 (Extended One-Generation Reproductive Toxicity Study)
- Principles of method if other than guideline:
- 13 week repeated dose study using animals which were exposed in utero
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Route of administration:
- oral: feed
- Vehicle:
- other: feed
- Details on exposure:
- F0 males and females were treated for four weeks prior to mating until scheduled sacrifice. The F1 male and female offspring were exposed in utero and from birth until the start of the 13-week study. The F1 offspring selected for the 13-week study were then provided the respective treated diets for 13-weeks.
- Details on mating procedure:
- Males and females cohabited for 1 week
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- P generation females were exposed to the diet during mating, gestation, littering and weaning. FI animals continued on the diet for 13 weeks.
- Frequency of treatment:
- daily
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 25
- Control animals:
- yes, plain diet
- Positive control:
- no
- Parental animals: Observations and examinations:
- Parental animals were evaluated for reproductive endpoints (mating performance, fertility, gestation length and parturition, litter size, numbers of implantations, survival and growth).. A full range of tissues were retained for the F0 males and females and reproductive organ tissues were retained for F1 males and females. Microscopic examinations were performed on a standard set of tissues for F0 males and females, as well as tissues found to be abnormal at necropsy.
- Oestrous cyclicity (parental animals):
- yes
- Sperm parameters (parental animals):
- yes
- Litter observations:
- yes
- Postmortem examinations (parental animals):
- yes
- Postmortem examinations (offspring):
- yes
- Statistics:
- For organ weights and body weight changes, homogeneity of variance was tested using Bartlett’s test followed by Behrens-fisher test or Dunnett’s test as appropriate. Macroscopic pathology and histopathology data were assessed using Fisher’s Exact test. Estrus cycles were analyzed using the Cochran-Armitage trend test. Other statistical tests used as appropriate were: Williams’ test for a dose-related response; Student’s t-test; Shirley’s non-parametric test for a dose-related response; Steel’s test; and Wilcoxon rank sum test. Significance level was p<0.05.
- Reproductive indices:
- yes, in intact females carrying to term
- Offspring viability indices:
- yes
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- There were no significant intergroup differences in the bodyweights of animals at the start of the 13 week toxicity study, and each toxicity and recovery phase group was composed of unrelated male and female siblings.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: NOAELs as published in the study report were reevaluated by US. EPA to be as described above.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- no
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There were no significant intergroup differences in the bodyweights of animals at the start of the 13 week toxicity study
- Food efficiency:
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects
- Key result
- Critical effects observed:
- no
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- A dietary toxicity study was undertaken to the analogue ATBC in weanling F1-generation Han Wistar male and female rats which had been exposed to the test material during gestation and weaning. The parental generation of these rats (P) had been exposed to this substance for 4 weeks prior to mating and 1 week during cohabitation. Doses were 100, 300 and 1000 mg/kg bw/d. There were no adverse effects observed in reproductive indices or in gross and histopathology in the P generation. There were no significant effects on sperm development or oestrus cycles. There were no adverse effects observed in gestation length, parturition, litter size, survival or growth of offspring. Necropsies of surplus offspring showed no adverse effects. The NOAEL for reproduction and for developmental toxicity was 1000 mg/kg bw/d. Data can be read-across between the structural analogues and target substance based on common breakdown products. This is adequate to fulfill the information requirements, to be the basis for classification and labelling decisions, and for risk assessment.
Reference
being 87-89% of target for males and 93-96% of target for females.
There was no effect of treatment upon the F1 generation before they were assigned to the Toxicity phase of this study at approximately four
weeks of age. The general condition of parental animals was unaffected by treatment. There were no macroscopic findings at necropsy of the P adults or surplus F1 offspring that were
attributable to treatment.Estrous cycles, mating performance, fertility, gestation length and parturition, were all unaffected by treatment. Litter size, survival and growth were similar in all groups and within expected historical control ranges. Although numbers of implantations and litter size at 1000 mg/kg/day were marginally lower than concurrent control group levels, they were within the laboratory’s historical control ranges. Anogenital distance and sexual maturation in both sexes and retention of areolae in male offspring were unaffected by treatment. There were no adverse effects on sperm motility, counts or morphology.
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- adequate
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Effects on developmental toxicity
Description of key information
No teratogenic effects
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: guideline study under GLP
- Justification for type of information:
-
An analogue approach is used for the hazard assessment of several human health endpoints. The hypothesis for the analogue approach is that data can be read-across from data-rich substances, namely acetyl tributyl citrate (ATBC, CAS 77-90-7), acetyl triethyl citrate (CAS 77-89-4) and triethyl citrate (TEC, CAS 77-93-0) to acetyl trihexyl citrate (ATHC, CAS 24817-92-3). The analogue approach is based on common breakdown products via physical and biological processes, and similar functional groups, according to Annex XI, Section 1.5, of Regulation EC No. 1907/2006. Read-across to ATHC is indicated in order to avoid unnecessary in vivo testing according to Article 25 of Regulation EC No. 1907/2006.
The analogue approach to evaluating the safety of triethyl citrate is adopted here, reflecting the approach used by various expert panels and authoritative bodies in their safety assessment of TEC, included JECFA, EFSA, U.S. FDA, EPA and CIR. The use of analogues for hazard evaluation is justified (Scenarios 1 and 2 of the RAAF, 2015) because the substances have common breakdown products via physical and biological processes, which reflects the similar functional groups in their chemical structure. The proposed analogues have similar functional groups, including: a citric acid (tricarboxylic acid) backbone, three short-chain alkyl esters, and an acetyl group (except for TEC). Other than the acetyl group, there are no other functional groups which may introduce additional toxicities. The substances display similar classification based on similar toxicities.
The target substance is expected to have essentially the same effect in the toxicity test/endpoint as does the source substance. Dose descriptors obtained for derivation of a DNEL are adequate and appropriate, and do not underestimate the hazards of the registered substance.
This information is adequate to fulfill the data requirements of Annex IX, to be the basis for classification and labelling decisions, and for risk assessment. - Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: OECD 408 modified
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: US EPA OPPTS 870.3100 modified
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- no analysis of uterine contents GD 20
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: OECD 433 EOGRTS
- Version / remarks:
- without extentions
- Principles of method if other than guideline:
- Four week repeated dose exposure to adult rats prior to mating, with gravid females exposed during gestation and weaning (6 weeks).
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- Wistar Han rats
- Route of administration:
- oral: feed
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analytical verification occurred; doses were not lower than target doses.
- Details on mating procedure:
- Males and females cohabitated and mated (1 week).
- Duration of treatment / exposure:
- P males and females were treated for four weeks prior to mating until scheduled sacrifice. They cohabitated and mated (1 week). After mating, males were sacrificed and toxicity was assessed . Females (P) were placed in separate cages and allowed to deliver, nurse and wean offspring, and then sacrificed. The F1 offspring were placed on test diets for 13 weeks. after which aa recovery groups was test material free for 4 weeks.
- Frequency of treatment:
- daily in feed
- Duration of test:
- 24 weeks (EOG) plus 4 weeks recovery
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 25
- Control animals:
- yes, plain diet
- Details on study design:
- At the completion of the in utero phase, F1 rats that had been exposed to test material from conception through gestation and continuously from the time of birth were selected (20 unrelated males and 20 unrelated females per dose group for the main study; and 10 unrelated males and 10 unrelated females for the control and high dose recovery groups) and transferred to the 13-week study.
- Maternal examinations:
- Parental animals were evaluated for reproductive endpoints (mating performance, fertility, gestation length and parturition, litter size, numbers of implantations, survival and growth), and F1 animals were evaluated for sexual maturation (balano-preputial separation, vaginal opening, anogenital distance, retained areolae in males, sperm assessments), estrous cyclicity, physical appearance, ophthalmologic effects, neurobehavioral effects, growth, food consumption, survival, hematology, blood chemistry, urinalysis, peroxisome proliferation, organ weights, gross pathology and histopathology. A full range of tissues were retained for theP males and females and reproductive organ tissues were retained for F1 males and females. Microscopic examinations were performed on a standard set of tissues for P males and females, as well as tissues found to be abnormal at necropsy.
- Ovaries and uterine content:
- Animals allowed to deliver litters naturally.
- Fetal examinations:
- F1 animals were evaluated for sexual maturation (balano-preputial separation, vaginal opening, anogenital distance, retained areolae in males, sperm assessments), estrous cyclicity, physical appearance, ophthalmologic effects, neurobehavioral effects, growth, food consumption, survival, hematology, blood chemistry, urinalysis, peroxisome proliferation, organ weights, gross pathology and histopathology. A full range of tissues were retained for the Pyes males and females and reproductive organ tissues were retained for F1 males and females.
- Statistics:
- For organ weights and body weight changes, homogeneity of variance was tested using Bartlett’s test followed by Behrens-fisher test or Dunnett’s test as appropriate. Macroscopic pathology and histopathology data were assessed using Fisher’s Exact test. Estrus cycles were analyzed using the Cochran-Armitage trend test. Other statistical tests used as appropriate were: Williams’ test for a dose-related response; Student’s t-test; Shirley’s non-parametric test for a dose-related response; Steel’s test; and Wilcoxon rank sum test. Significance level was p<0.05.
- Historical control data:
- yes
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Yellow staining of the perigenital and perianal areas of high dose females
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Details on results:
- Maternal toxic effects:no effects. There was no effect of treatment upon the F1 generation before they were assigned to the Toxicity phase of this study at approximately four weeks of age.
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Other effects:
- no effects observed
- Description (incidence and severity):
- Oestrous cycles, mating performance and fertility were unaffected by four weeks of exposure to tet material at dietary concentrations targeted to generate an intake of 1000 mg/kg/day.
- Details on maternal toxic effects:
- Maternal toxic effects:no effects. There was no effect of treatment upon the
F1 generation before they were assigned to the Toxicity phase of this study at approximately four
weeks of age.
Details on maternal toxic effects:
Estrous cycles, mating performance, fertility, gestation length and parturition, were all unaffected by treatment. Litter size, survival and growth were similar in all groups and within expected historical control ranges. Although numbers of implantations and litter size at 1000 mg/kg/day were marginally lower than concurrent control group levels, they were within the laboratory’s historical control ranges.
After 13 weeks of treatment, high bodyweight-relative liver weights were recorded for males and females that received 1000 mg/kg/day. This resolved on completion of the Recovery period.
Anogenital distance in both sexes and retention of areolar regions in male offspring were unaffected
by treatment.
There were no macroscopic findings at necropsy of the F0 adults or surplus F1 offspring that were
attributable to treatment. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: no effects
- Key result
- Abnormalities:
- no effects observed
- Fetal body weight changes:
- not examined
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- not examined
- Visceral malformations:
- not examined
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
Anogenital distance and sexual maturation in both sexes and retention of areolae in male offspring were unaffected by treatment. There were no adverse effects on sperm motility, counts or morphology. There were no findings at necropsy of surplus offspring that were considered to be treatment-related. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Conclusions:
- A dietary toxicity study of ATBC was undertaken in weanling F1-generation Han Wistar male and female rats which had been exposed to the test material during gestation and weaning. The parental generation of these rats (P) had been exposed to this substance for 4 weeks prior to mating and 1 week during cohabitation. Doses were 100, 300 and 1000 mg/kg bw/d. There were no adverse effects observed in reproductive indices or in gross and histopathology in the P generation. There were no significant effects on sperm development or oestrus cycles. There were no adverse effects observed in gestation length, parturition, litter size, survival or growth of offspring. Necropsies of surplus offspring showed no adverse effects. The NOAEL for reproduction and for developmental toxicity was 1000 mg/kg bw/d. Data can be read-across between the structural analogues and the target substance based on common breakdown products. This is adequate to fulfill the information requirements, to be the basis for classification and labelling decisions, and for risk assessment.
Reference
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- adequate
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Mode of Action Analysis / Human Relevance Framework
Not applicable
Justification for classification or non-classification
In a well-designed study (EOGRTS format) to investigate repeated dose toxicity as well as reproductive toxicity, ATBC was given in the feed to Wistar rats and toxicity assessed. There were no adverse reproductive or developmental effects and the NOAEL was 1000 mg/kg bw/d. These data are applicable to the target substance and are adequate for risk assessment and classification and labelling.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.